A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 4, 2026

Study Completion Date

December 15, 2027

Conditions
Myeloproliferative DisordersEssential ThrombocythemiaNeoplasmsMyelofibrosis
Interventions
DRUG

JNJ-88549968

JNJ-88549968 will be administered.

Trial Locations (26)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

12203

RECRUITING

Charite Campus Benjamin Franklin, Berlin

19104

RECRUITING

University of Pennsylvania, Philadelphia

28204

RECRUITING

Levine Cancer Institute, Charlotte

30625

RECRUITING

Medizinische Hochschule Hannover, Hanover

33612

RECRUITING

Moffit Cancer center, Tampa

37203

RECRUITING

Sarah Cannon Cancer Institute, Nashville

40138

RECRUITING

Policlinico Sant'Orsola Malpighi, Bologna

46010

RECRUITING

Hosp. Clinico Univ. de Valencia, Valencia

48109

RECRUITING

University of Michigan, Ann Arbor

52074

RECRUITING

Universitaetsklinikum der RWTH Aachen, Aachen

64239

RECRUITING

Tel Aviv Sourasky Medical Center, Tel Aviv

69120

RECRUITING

Universitaetsklinikum Heidelberg, Heidelberg

69495

RECRUITING

CH LYON SUD - Hematology, Pierre-Bénite

75475

RECRUITING

Hopital Saint Louis, Paris

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

93053

RECRUITING

Universitaetsklinikum Regensburg, Regensburg

3436212

RECRUITING

Carmel Medical Center, Haifa

5266202

RECRUITING

Sheba Medical Center, Ramat Gan

9112001

RECRUITING

Hadassah University Hospita Ein Kerem, Jerusalem

M5G 1Z5

RECRUITING

Princess Margaret Cancer Centre University Health Network, Toronto

H3T 1E2

RECRUITING

Jewish General Hospital, Montreal

08916

RECRUITING

Hosp. Univ. Germans Trias I Pujol, Badalona

NW1 2PG

RECRUITING

University College London Hospitals Nhs Foundation Trust, London

OX3 7LE

RECRUITING

Churchill Hospital, Oxford

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY